USA flag logo/image

An Official Website of the United States Government

S-nitrosothiol analyzer for the clinical diagnosis of cardiovascular disease…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93937
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL095181
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
ACCORD BIOMATERIALS, INC.
ACCORD BIOMATERIALS, INC. 3550 W LIBERTY RD, STE 3 ANN ARBOR, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: S-nitrosothiol analyzer for the clinical diagnosis of cardiovascular disease mark
Agency: HHS
Contract: 2R44HL095181-02
Award Amount: $1,388,920.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this study is to develop a novel electrochemical S-nitrosothiol (RSNO) sensing system with an optimized detection limit and to finalize the specifications required to build a practical RSNO tool for clinical diagnostic applications. RSNO's are a primary carrier and reservoir of NO in vivo and are a potential pre-symptom marker for hypertensive disorders, endothelial dysfunction, cardiovascular risk and inflammation. However, the clinical significance of endog enous RSNO levels cannot be fully realized as a vascular diagnostic tool or biomarker without a quick and convenient assay for RSNO's. Compared to existing RSNO assay techniques, the proposed electrochemical RSNO sensor is highly sensitive and selective, i s capable of rapidly measuring RSNO's in blood without separation or pretreatments and is suitable for simple and robust point-of-care use as a clinical diagnostic. A novel catalytic membrane will be prepared by covalently modifying cellulose dialysis memb ranes with selenocystamine to enhance the sensitivity of the RSNO sensor. The design parameters, including appropriate blood dilution ratios, light protection, temperature control, sensor/reagent stability and the tolerance to varying levels of blood compo nents (e.g. hematocrit/hemoglobin) will be determined in Phase I and will serve as the criteria to build and validate the prototype point-of-care RSNO assay that will be assessed as a biomarker for pulmonary arterial hypertension (PAH) in Phase II. PUBLIC HEALTH RELEVANCE: The goal in this grant is to develop a novel electrochemical S-nitrosothiol (RSNO) sensor with enhanced limit of detection, and to determine the specifications to use this RSNO sensor as the detector to build a practical RSNO analy zer for clinical diagnostic applications, first for trial in pulmonary arterial hypertension (PAH). Currently there is no quick and convenient technique to measure endogenous RSNO concentrations reliably.

Principal Investigator:

Ronald J. Shebuski
7038455429
RSHEBUSKI@GMAIL.COM

Business Contact:

Kimberly Kowalski
kkowalski@accordbiomaterials.com
Small Business Information at Submission:

ACCORD BIOMATERIALS, INC.
ACCORD BIOMATERIALS, INC. 3550 W LIBERTY RD, STE 3 ANN ARBOR, MI -

EIN/Tax ID: 126307643
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No